U.S. Software Stock News

Viatris stock has returned 76.1% over the past year, yet its valuation checks still lean cheap, which puts the recent share price strength under scrutiny for investors trying to judge whether the current level around US$16.43 offers enough long term value support. Viatris has delivered a 76.1% gain over the last 12 months, which makes it important to ask whether the current price already reflects much of the good news. The recent FDA approval for the once weekly Gwyn Lo contraceptive patch...

In late July 2026, Modine Manufacturing Company reported first-quarter fiscal 2027 results showing sales of US$874.1 million and net income of US$73.9 million, alongside diluted EPS from continuing operations of US$1.37, and also confirmed it had completed a previously announced buyback of 230,000 shares for US$18.4 million after repurchasing no shares in the most recent quarter. Beyond the quarterly performance, management’s new fiscal 2027 guidance calling for net sales to increase by a...

Upwork stock is trading near US$9.67 after a difficult few years, and the valuation checks suggest the market may now be pricing it cautiously despite a recent short term rebound. Upwork shareholders have seen the stock decline about 77.3% over the past 5 years, which sets a low bar for any case that today’s price already reflects the company’s potential. The key swing factor for valuation is whether Upwork can turn its marketplace scale into consistently stronger profitability, while the...

Warrior Met Coal (HCC) is back in focus after its 5 August 2026 earnings release. The company reported updated quarterly results, revised full year 2026 volume guidance, new production targets, and a reaffirmed cash dividend. See our latest analysis for Warrior Met Coal. Warrior Met Coal’s latest earnings and higher 2026 volume guidance have come alongside strong price momentum, with a 7 day share price return of 15.82% and a 1 year total shareholder return of 51.87% pointing to rising...

NI Holdings stock barely moved after earnings, with a 0.5% gain that suggests investors shrugged at the headline. That calm reaction contrasts with a quarterly profit line that almost vanished. Basic earnings per share for Q2 came in around flat at just over US$0.01, following a far stronger start to 2026. The key issue for NI Holdings now appears to be sentiment. The stock carries a trailing P/E of 40.8x while net profit margin sits under 3%. That mix raises a clear question for investors...

Syndax Pharmaceuticals has delivered a 63.5% gain over the past year, yet the broader valuation checks and current market multiples suggest the stock is not an obvious bargain at today’s price of US$20.40. The 63.5% one year return points to strong recent optimism already reflected in Syndax Pharmaceuticals' share price. Progress on its oncology pipeline and upcoming clinical data can support expectations for future revenue, while the execution and clinical risks around those same programs...

Wendy’s stock bounced about 4% to US$7.69 into the first full trading day after earnings, even as the headline story is pressure, not comfort. Same restaurant sales declined 6.3% in the quarter and global systemwide sales fell 6.5%. That mix of a cheaper stock on an earnings pop and falling traffic is what matters for you as an investor. In the near term, the focus is on weaker guest counts and a thinner 5.7% trailing net margin. Over the longer term, the key question is whether the new...

The fight over Fifa’s abandoned $4.2b World Cup stake has drawn attention to something bigger. Tech investors are hunting for assets that feel resilient as AI reshapes movies, games and streaming, and global sports sit right in that crosshairs. For anyone focused on where long term attention and money may concentrate, this matters. This article breaks down three stocks tied to that story and explains how the same news affects each of them. Manchester United (MANU) Manchester United runs one...

Ziff Davis (ZD) stock is in focus after the company reported second quarter 2026 results, with sales of US$286.74 million, a sharp swing in net income, and a loss from continuing operations. See our latest analysis for Ziff Davis. The earnings update and the sale of the connectivity business to Accenture for about US$1.2b have come alongside strong recent momentum in Ziff Davis, with a 90 day share price return of 28.58% and a 1 year total shareholder return of 46.86%, although the 5 year...

In early August 2026, MetLife, Inc. reported second-quarter revenue of US$19,154 million and net income of US$736 million, alongside higher diluted earnings per share from continuing operations versus a year earlier, and stronger results for the first half of 2026. On the same day, MetLife’s board authorized a new US$3.00 billion share repurchase program after completing US$2.63 billion of buybacks since April 2025, underscoring the insurer’s current emphasis on returning capital to...

Gray Media stock exploded 25% higher to US$5.37 after the Q2 report, a sharp move for a regional television and media operator that has been wrestling with losses. The headline number was Q2 revenue of US$839 million, helped by US$83 million of political advertising that came in ahead of expectations. Basic earnings per share remained in loss territory, although the loss narrowed compared with recent quarters. For short term traders, the pop is the story. For longer term holders, the bigger...

Zai Lab stock has rebounded sharply over the short term, yet its longer term share price record and current valuation checks point to a more cautious picture for investors trying to judge what the recent move really means. Over the past 5 years, Zai Lab has fallen about 84.5%, which leaves long term holders with a material drawdown even after the recent bounce. Regulatory progress such as Orphan Drug Designation for its DLL3-targeting therapy Zocilurtatug Pelitecan can support expectations...

Celldex Therapeutics stock has more than doubled over the past year, yet the latest valuation checks and market multiples suggest the shares lean expensive rather than clearly cheap. The 101.9% return over the past year highlights how strongly sentiment has shifted toward Celldex Therapeutics, which raises the bar for what the current price can justify. Progress in Celldex Therapeutics' barzolvolimab and CDX-622 programs can support expectations for future growth. However, trial setbacks or...

Annaly Capital Management stock triggered review Annaly Capital Management (NLY) is back on investor radar after recent share price moves, with the stock closing at US$23.04 on 5 August 2026 and showing mixed short term and longer term returns. See our latest analysis for Annaly Capital Management. The recent 1 day share price return of 1.68% adds to a steady but modest trend over the past quarter, while total shareholder return of 27.54% over one year and 73.59% over three years highlights...

Owens Corning recently reported past second-quarter 2026 results showing broadly flat sales of US$2,756 million but a sharp drop in net income to US$226 million, while also completing share repurchases totaling about 13% of its stock under programs launched in 2022 and 2025. Alongside these earnings, the company announced a finance leadership reshuffle that elevates long-time insider Todd Fister to President and COO and brings in experienced CFO Jonathan Collins, signaling a renewed emphasis...

Why Smurfit Westrock Stock Is Back In Focus After Q2 2026 Smurfit Westrock (NYSE:SW) is drawing fresh attention after its second quarter 2026 update, which combined higher net income, firm cost control and an affirmed dividend, along with plans to pursue acquisitions in its Latin American operations. See our latest analysis for Smurfit Westrock. Smurfit Westrock’s recent Q2 update, including higher net income, affirmed dividends and a focus on Latin American acquisitions, has coincided with...

Integer Holdings (ITGR) has agreed to be acquired by KKR in an all cash deal that values the company at about US$5.7b. The transaction price of US$127 per share provides a clear reference point for investors. See our latest analysis for Integer Holdings. The KKR offer has pulled Integer Holdings' share price closer to the US$127 deal value, with a 30-day share price return of 33.72% and year to date share price return of 63.15%. The 1-year total shareholder return is 17.68%, signalling that...

Sylvamo jumped 8.7% to US$41.07 after earnings, an eye catching move for a mature paper producer. The headline is not revenue, which came in at US$806 million, or the adjusted earnings that hovered near breakeven. The real story is pressure on profitability. Quarterly results showed a loss per share and followed a weak first quarter, while the trailing net margin now sits in the low single digits. Short term traders see a rebound story. Long term investors need to weigh a margin squeeze...

Ivanhoe Electric (IE) has drawn fresh attention after reporting second quarter 2026 results, with revenue and earnings per share coming in below analyst expectations and investors focusing on management’s latest commentary. See our latest analysis for Ivanhoe Electric. The latest earnings miss comes after a mixed year for Ivanhoe Electric, with the share price up 20.7% over the past month but down 32.6% year to date and a 3 year total shareholder return that remains weak at 32.18% decline...

Chefs' Warehouse stock has delivered a very large 270.7% return over the past five years, yet the current valuation checks send mixed signals. An intrinsic value estimate from a Discounted Cash Flow (DCF) model points to upside, while earnings-based multiples appear expensive. After a strong run, the stock now sits at the center of a valuation debate rather than looking clearly cheap or clearly overvalued. Over five years, Chefs' Warehouse has returned 270.7%, which puts extra focus on...

Alamar Biosciences (NasdaqGS: ALMR) announced the launch of its NULISAseq Immune 340 Panel, aimed at profiling hard to measure immune system proteins across multiple disease areas. The company expanded its partnership with ALZpath to advance blood based diagnostics for Alzheimer's disease using ALZpath's phosphorylated tau 217 (pTau217) antibody. Management positions the two updates as strengthening Alamar's role in translational research, drug development, and precision medicine...

PPL stock was already grinding through a soft patch, down over the past month and quarter, yet it popped about 2.4% to US$35.46 after the latest earnings. The market reacted positively in the near term. The company reported Q2 ongoing earnings per share that aligned with its plan and kept full-year guidance intact. The real story for long-term holders is not this quarter’s modest utilities-style EPS. It is the tension between a richer P/E multiple, a capital-heavy expansion plan, and balance...

Fresh jobs data showing a surprise loss of 23,000 U.S. roles in July and a softer labor force is pushing investors to rethink where steady income might come from next. With the Federal Reserve now more likely to sit tight or turn more cautious on rates, dividend income stocks are back in focus. This article walks through three large cap dividend stocks that appear closely tied to this shifting jobs story. The three stocks below are just a starting sample, and the full screen surfaced 23 more...

The market pushed CBL & Associates Properties up 4.1% to US$56.55, even though the headline Q2 story is quieter than that price move suggests. For a retail REIT, the key yardstick is Funds From Operations, and FFO for the quarter sits at US$59.9m on revenue of US$146.5m. The trailing picture shows earnings that are flattered by a very large one off gain. Yet the stock still trades on a low trailing P/E of 8.2x. That mix of emotional buying and complicated fundamentals sets the stage for a...